Immunotherapy may replace chemo in HPV throat cancer trial
NCT ID NCT03410615
First seen Jan 16, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This study compares standard chemoradiation (cisplatin plus radiation) to two immunotherapy-based approaches for patients with HPV-positive throat cancer that has spread to lymph nodes but not elsewhere. Participants receive either durvalumab (an immunotherapy) with radiation, followed by durvalumab alone, or the same plus another immunotherapy (tremelimumab) after radiation. The goal is to see if these newer treatments can better prevent the cancer from returning, while possibly reducing side effects. The trial involves 129 adults and is currently active but no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Sint Augustinus
Wilrijk, B-2610, Belgium
-
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1, Canada
-
CIUSSS de l'Estrie - Centre hospitalier
Sherbrooke, Quebec, J1H 5N4, Canada
-
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9, Canada
-
Clinique St. Elizabeth
Namur, 5000, Belgium
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Complejo Hospitalario de Navarra
Pamplona, Navarre, 31008, Spain
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Health Sciences North
Greater Sudbury, Ontario, P3E 5J1, Canada
-
Hospital Duran i Reynals
Barcelona, 08907, Spain
-
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2, Canada
-
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7, Canada
-
London Regional Cancer Program
London, Ontario, N6A 5W9, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
QEII Health Sciences Centre
Halifax, Nova Scotia, B3H 1V7, Canada
-
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4, Canada
-
The Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
The Research Institute of the McGill University
Montreal, Quebec, H4A 3J1, Canada
-
University Clinical Hospital of Valencia
Valencia, 46010, Spain
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
-
University Hospital Leuven
Leuven, B-3000, Belgium
-
University Hospital Ramon y Cajal
Madrid, 28034, Spain
-
University Hospital Vall dHebron
Barcelona, 08035, Spain
-
University Hospital of Antwerp
Edegem, Belgium
-
University Hospital of Gent
Ghent, 9000, Belgium
Conditions
Explore the condition pages connected to this study.